
|
ClopidogrelFor the strength of the evidence for efficacy, the following will be considered: Design of available studies according to standard hierarchy I to V systematic reviews, RCTs, nonrandomised trials, abstracts, opinions, etc. ; Systematic reviews or RCTs are required for drugs to be given a Q1 or rating. Quantity and quality of studies JADAD score, intention-to-treat analysis, power calculation, etc. ; Are there comparisons with other drugs? How well did the drug work in these studies, comparatively? How safe was the drug in the trials? What adverse events were reported? Any other relevant factors? For the place of the drug in therapy in primary care, the following will be considered: How safe is the drug in intended use over a realistic time-frame? Is there a need for this drug in primary care are there other options available ; ? Is there a need for specialist supervision or monitoring? How likely is it that prescribing will occur in primary care? Is there relevant NICE guidance? Is cost a consideration? Are there any cost-effectiveness and quality of life data? Any other relevant factors? For examples, see the new Verdict & Summary sheets for clopidogrel and dipyridamole.
Ticlodipine Ticlid-generic only ; . DRUG CLASS PLATELET AGGREGATION INHIBITORS Implement 3 5 03 NON-PREFERRED aspirin * OTC ; aspirin dipyridamole ER Aggrenox ; clopidogrel Plavix ; dipyridamole Persantine ; * ticlopidine Ticlid. Pediatric Associates of Iowa City and Coralville is participating with the Iowa Medicaid program. We require that a card be presented before every visit to confirm eligibility. If the physician's name on the card is not on staff at Pediatric Associates, it is the patient's responsibility to call 1-800-338-9154 to get the name changed to their primary physician at our office. Until a cor and cloxacillin. On 13-Apr-2005. All patents expired but various PED expiry in Oct-05, Jan-08, Feb-09 Carvedilol 25-Feb-04 Coreg GSK 670 Mar-2007, 2015, 2017 Sertraline Hydrochloride Form II ; 15-Apr-04 Zoloft Pfizer 2, 200 30-Jun-2006, Teva, Ranbaxy and DRL hold tentative approvals. Teva has Para-III filing Ivax & Pfizer have settled their dispute. Ivax may license Pfizer' patents to s launch a authorized generic post expiry of patent + PED ; in Jun-2006. Ivax has received tentative approval on 10-Dec-04. Teva also has a Para-IV filing. Andrx, Genpharm, Aurobindo, Mylan, Roxane hold tentative approvals Terbinafine Hydrochloride Lopidogrel Bisulphate 25-May-04 Plavix Sanofi 1, 900 2011, Lamisil Novartis 460 Dec-06 Cipla' partner may not have FTF. s Teva has a Para-III filing and holds tentative approval Cipla has partnered with Watson. Apotex and DRL have filed before Watson Sumatriptan Succinate 25-May-04 Imitrex GSK 800 28-Jun-2007, 2009, Irinotecan Hydrochloride 8-Jun-04 Trihydrate Lamivudine 19-Jul-04 Epivir GSK Camptosar Pfizer 20-Feb-2008, No ANDAs approved till date 2020 May-2010, Nov-2016, Jul-2018 Rizatriptan Benzoate 30-Aug-04 Maxalt Merck N.A. 2012 Cipla' partner has filed Para-IV s on 02-Sep-2004 with FTF status. Cipla is the only DMF filer till date. No ANDAs approved till date Stavudine Finasteride Prosacar 31-Aug-04 9-Sep-04 Zerit Propecia BMS Merck 370 Dec-08 19-Jun-2006 compound Aurobindo holds tentative approval Mylan lost summary motion in Oct-05. Ivax, Teva & DRL hold tentative Ivax expects its 180-day exclusivity to start in mid-2006 Pantoprazole Sodium Sesquihydrate Lorazepam 20-Oct-04 Ativan 30-Sep-04 Protonix Altana mktd in US by Wyeth ; Biovail Expired 1.600 2010, 2016 Para-IV filed on 02-Feb-2004. Cipla' s partner may not have FTF. No ANDAs approved till date Many generic players Y Y-DMF outsourced Ranbaxy & Aurobindo hold tentative approvals Ranbaxy, Cobalt hold tentative approvals Y Y-DMF outsourced Y Y. Several of these medications may be topical or those that are applied on the surface of the skin, others are systematic or the drugs that are taken orally and cromolyn, for example, clopidogrel order. 47% of the inappropriate prescribing was due to aspirin being changed to clopidogrel when alternative actions would have been more suitable. Reasons and suggested actions as per the guideline included: dyspepsia; o minimise contributory factors, eg alcohol or NSAIDs, then add lansoprazole or omeprazole, history of GI bleed; o use PPI as gastroprotection, minimise other risk factors, patient suffered CVA TIA on aspirin; o add dipyridamole. True aspirin allergy is a contra-indication to aspirin. All antiplatelets are contra-indicated in: GI bleeding 6months ago active peptic ulceration, breast feeding, haemophilia bleeding disorders. Other ways in which prescribing was inappropriate included: first line use for an indication where aspirin is as effective and there were no contraindications to aspirin, clopidogrel being added to aspirin with no evidence of clinically significant benefit. dual therapy aspirin plus clopidogrel ; being continued for too long, eg after stenting. Work in 16 practices to change patients to more appropriate therapy realised potential annual savings of 207k. The findings are being fed back to secondary care clinical directors and prescribers. Work is underway to improve guideline adherence among secondary care prescribers. ISOTRETINOIN: The SPC for isotretinoin Roaccutane ; has changed. Prescribing must be by or under the supervision of physicians with expertise in the use of systemic retinoids for severe acne and a full understanding of the risks and monitoring requirements. GPs could continue prescribing initiated by a specialist. The ADTC reviewed the change due to concerns expressed by dermatologists about the stringent need for monitoring and appropriate cessation of therapy. The Formulary status remains that isotretinoin is restricted to use in hospitals, under specialist dermatological supervision. TRAVEL VACCINES: Red Book vaccines are in the Global Sum and should be supplied and administered on the NHS. They are: Cholera Diphtheria Tetanus Polio Hepatitis A MMR Rubella Typhoid. All other travel vaccinations can be charged for if prescribed privately. No charge can be made for administration or accompanying advice given with an NHS prescription. For full information on prescribing for travel, see PSPC June 2005 on the ADTC website glasgowformulary ot.nhs.
PII-88 DEVELOPMENT OF FAST AND ACCURATE CHEMICAL HYDROLYSIS METHOD FOR CYP2D6 ACTIVITY ASSESSMENT USING DEXTROMETHORPHAN AS PROBE IN A POPULATION OF FIBROMYALGIA PATIENTS. Y. Daali, PharmD, J. Chabert, PhD, V. Piguet, MD, M. Rebsamen, PhD, M. Rossier, PhD, P. Dayer, Prof, J. A. Desmeules, MD, Geneva University Hospitals, Geneva, Switzerland. PII-89 EFFECT OF KETOCONAZOLE ON THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF CLOPIDOGREL AFTER ORAL ADMINISTRATION IN HEALTHY SUBJECTS. S. Y. Eum, J. R. Kim, MD, K. S. Lim, MD, J. W. Kim, MD, B. H. Kim, MD, M. G. Kim, MD, MS, Y. J. Chung, MD, T. E. Kim, MD, J. Y. Jeon, Y. M. Tae, J. Y. Cho, PhD, K. S. Yu, MD, PhD, S. G. Shin, MD, PhD, I. J. Jang, MD, PhD, Department of Pharmacology and Clinical Pharmacology Unit, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. PII-90 POMEGRANATE JUICE DOES NOT IMPAIR CLEARANCE OF ORAL OR INTRAVENOUS MIDAZOLAM: COMPARISON WITH GRAPEFRUIT JUICE D. Farkas, PhD, L. E. Oleson, Y. Zhao, M. A. Zinny, M. H. Court, D. J. Greenblatt, Tufts University, Boston, MA. PII-91 POPULATION PHARMACOKINETICS OF DOXORUBICIN IN INFANTS AND CHILDREN WITH MALIGNANT DISEASES. Y. Finkelstein, MD, A. A. Nava-Ocampo, MD, E. St. Pierre, MSc, T. Schechter, MD, S. Walker, PharmD, G. Koren, MD, Div. of Clinical Pharmacology & Toxicology, Hospital for Sick Children, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. PII-92 IS MORPHINE ADMINISTRATION TO CHILDREN WITH SICKLE CELL DISEASE AND VASO-OCCLUSIVE CRISIS ASSOCIATED WITH AN INCREASED RISK FOR THE DEVELOPMENT OF ACUTE CHEST SYNDROME: A CASECROSSOVER STUDY. Y. Finkelstein, MD, F. Garcia-Bournissen, T. Schechter, MD, L. Nurmohamed, G. Koren, MD, Hospital for Sick Children, Toronto, ON, Canada. PII-93 PROTEIN BINDING OF LABETALOL IN PREGNANCY. S. Choi, K. Deyo, H. Jeong, J. H. Fischer, University of Illinois at Chicago, Chicago, IL. PII-94 INCREASED ABSORPTION OF CYCLOSPORIN IN THE PUROMYCIN AMINONUCLEOSIDE-INDUCED NEPHROSIS WITH DIFFERENT REGULATIONS OF CYP3A AND MDR1 EXPRESSION IN THE INTESTINE AND LIVER. T. Fujita, MD, PhD, S. Yasuda, BS, K. Fujita, Dr., Y. Kumagai, MD, PhD, M. Majima, MD, PhD, Y. Ohtani, MD, PhD, Kitasato University School of Medicine, Kitasato University School of Allied Health Sciences, Sagamihara, Japan and decadron. Discharge on lifestyle modifications and drug therapies for secondary prevention. They should also be given instructions on recognition of cardiac symptoms and what action to take if any symptoms occur. Ideally, family members should learn about cardiopulmonary resuscitation. In addition, health care professionals should be educated on all secondary prevention goals. The blood pressure goal is less than 140 90 mm Hg lower and less than 130 80 mm Hg patients with diabetes or chronic kidney disease.5, 6 Lipid management goals call for a LDL cholesterol substantially less than 100 mg dL, triglycerides less than 150 mg dL, and non-HDL cholesterol substantially less than 130 mg dL.5 Statin therapy with lifestyle modifications are usually needed to reach these goals. In diabetic patients, the goal HBA1C should be less than 7%.5 It is also reasonable for the goal LDL to be less than 70 mg dL in diabetic patients with CVD.7 Smoking cessation, weight management, and physical activity are also essential in management of these patients. Finally, antiplatelet agents, -blockers, and ACE-I should be continued daily in all post- STEMI patients without contraindications.5 Anti-Thrombotic Agents Aspirin at a dose of 75 to 162 mg should be given daily to achieve an anti-thrombotic effect causing near total inhibition of thromboxane A2. The Antiplatelet Trialists' Collaboration found up to a 25% decrease in recurrent cardiovascular events such as MI, stroke, and vascular death in patients who were receiving extended-duration antiplatelet therapy.8 Xlopidogrel at a daily dose of 75 mg can be substituted for those patients with an aspirin contraindication.5 If the patient has a stent implanted, then combination therapy with aspirin and clppidogrel is indicated. The duration of the. Medication form quantity treat angina to blood pain ; heart attacks and dexamethasone. ANTIPLATELETS All patients with no clear signs of bleeding, who are not on antic oagulation, should be taking an antiplatelet agent i.e. aspirin 300mg stat. then 75mg daily ; or a combination of low dose aspirin and dipyridamole modified release MR ; . Where patients are truly aspirin intolerant an alternative antiplatelet agent dipyridamole MR 200mg twice daily or clopidogreel 75mg daily ; should be used. Increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 31715. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Coll Cardiol 2005; 45: 1753 Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Coll Cardiol 2005; 45: 1748 Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R, et al. Findings of intravascular ultrasound during acute stent thrombosis. Heart 2004; 90: 14559. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogre resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 8592. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295302. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201 and divalproex and clopidogrel. You have been given a medicine called clopidogrel. But, three unwanted things often happen with prolonged drug use: 1 ; our bodies can build up a tolerance to the drug so that it requires more of it to get the same effect and tolterodine. Clopidogrel efficacyClopidogrel pharmacologyLINCOLNSHIRE COUNTY-WIDE TRUST CLINICAL PRESCRIBING GROUP TRAFFIC LIGHTS SYSTEM 2005 6 GREEN LIST DRUG PREPARATIONS RECOMMENDED FOR GP PRESCRIBING WITH SOME DEGREE OF CONSTRAINT BUT WITHOUT A QUALIFYING SHARED CARE ARRANGEMENT ; BNF Subsection & Title 2.9 Antiplatelet drugs Drugs Clopidogreo Plavix ; Comments Aspirin dispersible 75mg daily is the recommended first line antiplatelet agent in patients with angina or peripheral arterial disease PAD ; or following MI, stroke or TIA. Clpidogrel is only appropriate in patients hypersensitive to aspirin or with a known serious intolerance or contraindication to the use of aspirin. Problematic or ongoing dyspepsia with aspirin can be better resolved with concurrent antacid or aspirin EC Even aspirin plus a concurrent PPI is more cost-effective than clopidogrel. In PAD or following MI, clopidogrel is an appropriate second line agent after aspirin. Following stroke or TIA, clopidogrel is a third line agent after aspirin and dipyridamole. NICE have recently endorsed the first-line use of combination low-dose aspirin and MR dipyridamole for 2 years in patients following TIA or stroke. After two years MR dipyridamole should be discontinued and only low-dose aspirin maintained. In the GW Pharmaceuticals article in issue 4, we did not give the full name of Valerie Corral of WAMM, in the middle of the photo, between Matt Elrod on the left and David Hadorn on the right. The picture was taken on the Sunshine Coast while attending Rene Bojees wedding. WAMM was raided a few months earlier by federal agents who were later prevented from leaving the WAMM property by members blocking the driveway. Members took down the blockade when, after being released, Val asked them to. It was sort of a hostage exchange. Coincidental to the picture, Val and WAMM collaborated with GW on a whole cannabis strain analysis. WAMM recorded patient impressions of dif ferent strains for treating various symptoms and cloxacillin. One positive development is that PNG now has a national diabetic association the Diabetic Association of Papua New Guinea was established in 1999. The small but active association is involved with community awareness, and is about to start a revolving fund for glucose meters and strips. The Association has been welcomed into membership of the International Diabetes Federation. You're on a stable dose of thyroid hormone, but your body's ability to house thyroid hormone has fluctuated. ACS is a term used to refer to any group of clinical symptoms associated with acute myocardial ischaemia. Non ST-segment elevation ACS is classified as either unstable angina Troponin negative ; or non-ST-segment-elevation myocardial infarction Troponin positive ; . Evidence base Combination therapy of aspirin and clopidogrel is associated with a 2.1% absolute reduction in death from CV causes, non-fatal MI or stroke. For every 96 patients treated with an aspirin clopidogrel combination, instead of aspirin alone, for 9 months, 2 were prevented from either dying or having a non-fatal MI or stroke. However this combination is associated with a significant increase in the rate of major bleeding. For every 100 patients treated with the combination compared to aspirin alone, for 9 months, one would suffer a major bleed associated with clopidogrel. CURE Study ; Formulary choice Clopidogrel 75mg may be prescribed in combination with Aspirin 75mg following an episode of acute coronary syndrome for 12 months, and then discontinue clopidogrel. Treatment should be discontinued in patients who have been on this combination for longer than 12 months unless a longer course has been specified by the cardiologists. 26. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004; 127: 1123-1130. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Eng J Med. 2004; 350: 114-124. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004; 30: 1873-1881. Rinder HM, Snyder EL, Tracey JB, et al. Reversibility of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion. 2003; 43: 1230-1237. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or injured mouse platelets. Blood. 2003; 102: 4229-4235. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003; 112: 87-97. Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP. Glycosylation restores survival of chilled blood platelets. Science. 2003; 301: 1531-1534. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004; 44: 1325-1331. Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RM Jr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg. 2002; 235: 820-827. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg. 2005; 79: 1210-1216. Eagle KA, Guyton RA, Davidoff R, et al. ACC AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines Committee to update the 1999 guidelines for coronary artery bypass graft surgery ; . J Coll Cardiol. 2004; 44: e252-e253. CASE REPORT A 74-year-old white woman was admitted to the University of Cincinnati Medical Center with a 3-day history of profound weakness, shortness of breath, and tea-colored urine. Her medical history was remarkable for coronary artery disease and a transient ischemic attack. Her medications included simvastatin 40 mg once daily, clopidogrel 75 mg once daily, and nefazodone 150 mg twice daily. The patient had experienced progressive muscle pain and weakness since she had begun treatment. This emedtv page takes an in-depth look at these and other trilafon warnings and precautions, and explains who should not take the medication.
Clopidogrel is a potent antiplatelet agent that has been shown to be superior to aspirin1, 3 and to have a synergistic antiplatelet effect when combined with aspirin.18 In a wide variety of clinical studies across a wide spectrum of cardiovascular diseases, clopidogrel has had superior efficacy when combined with aspirin as compared with aspirin alone.69, 19 Clopidogrel is an effective, safe, and a cost-effective treatment that continues to be unfunded by PHARMAC for many New Zealanders who would be expected to benefit from its use. Author information: Harvey D White, Director of the Coronary Care and Green Lane Cardiovascular Research Unit, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland; Chris J Ellis, Cardiologist, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland. Acknowledgement: We are grateful to Charlene Nell and Barbara Semb for excellent secretarial assistance. Correspondence: Professor Harvey White, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92 024, Auckland 1030. Email: harveyw adhb.govt.nz References. Clopidogrel in strokeLightheadedness lack of sleep, endothelium dependent dilation, department of health and human services jobs texas, runny nose more for_patients and euphoria flushing mi. Kinetic 1 48 f-16, hyperparathyroidism natural remedies, ankle sprain wikipedia and conditioning coach or compound microscope resolving power. Clopidogrel drugHistory of clopidogrel, clopidogrel korea, clopidogrel efficacy, clopidogrel pharmacology and clopidogrel in stroke. Clopidogrel drug, ticlopidine vs clopidogrel, clopidogrel vs plavix and pci cure clopidogrel or clopidogrel aspirin cost benefit. © 2005-2008 Canada.my3gb.com, Inc. All rights reserved. |